
|Videos|November 25, 2013
The Treatment of Hairy Cell Leukemia
Author(s)Jae Park, MD
Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, comments on the treatment of patients with hairy cell leukemia.
Advertisement
Clinical Pearls
Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, comments on the treatment of patients with hairy cell leukemia.
- Patients with hairy cell leukemia typically receive cladribine or pentostatin and experience a long remission
- Patients are able to respond again to cladribine or pentostatin following relapse
- There are limited options for those who have gone through many lines of therapy
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5


























